Could Tecentriq cause a rush of repurposed drugs combo trialing with LL, given Mrs. Petersons status
Repurposed drugs are increasingly used to enhance the effectiveness of immune checkpoint inhibitors (ICIs) by modulating the tumor microenvironment, reducing resistance, and boosting T-cell activity.
Key agents include metformin, aspirin, statins, and beta-blockers, which can improve patient outcomes and overcome resistance to anti-PD-1/PD-L1 therapies.
PubMed Central (PMC) (.gov)
+4
Key Repurposed Drugs and Mechanisms
Metformin:
A diabetes drug that can boost anti-tumor immune responses and reduce PD-L1 expression.
Aspirin & NSAIDs:
Celecoxib inhibits COX-2 receptors and reduces inflammation-driven resistance to checkpoint inhibitors.
Statins:
Lipid-lowering drugs (e.g., fenofibrate) can reprogram the tumor microenvironment and improve response rates.
Beta-blockers:
Propranolol may improve overall survival in melanoma patients receiving immunotherapy.
JAK Inhibitors:
Used with anti-PD-1 (e.g., pembrolizumab) to reverse resistance, particularly in lung cancer.
Targeted Therapies:
Small molecule inhibitors (SMIs) targeting VEGFR, BRAF, or EGFR can also enhance T-cell infiltration and function.
Other Potential Agents:
Vitamin D, antidepressants (SSRIs), bisphosphonates, and TGF-inhibitors.
Cancer Biology & Medicine
+6
Potential Advantages
Improved Efficacy:
Combining these agents with ICIs like nivolumab or pembrolizumab can reduce tumor growth more effectively than either agent alone.
Reduced Side Effects:
Some repurposed drugs can decrease immune-related adverse events.
Lower Costs:
Repurposed drugs are generally affordable and already approved for safety.
Cancer Biology & Medicine
+4
Repurposed drugs are increasingly used to enhance the effectiveness of immune checkpoint inhibitors (ICIs) by modulating the tumor microenvironment, reducing resistance, and boosting T-cell activity.
Key agents include metformin, aspirin, statins, and beta-blockers, which can improve patient outcomes and overcome resistance to anti-PD-1/PD-L1 therapies.
PubMed Central (PMC) (.gov)
+4
Key Repurposed Drugs and Mechanisms
Metformin:
A diabetes drug that can boost anti-tumor immune responses and reduce PD-L1 expression.
Aspirin & NSAIDs:
Celecoxib inhibits COX-2 receptors and reduces inflammation-driven resistance to checkpoint inhibitors.
Statins:
Lipid-lowering drugs (e.g., fenofibrate) can reprogram the tumor microenvironment and improve response rates.
Beta-blockers:
Propranolol may improve overall survival in melanoma patients receiving immunotherapy.
JAK Inhibitors:
Used with anti-PD-1 (e.g., pembrolizumab) to reverse resistance, particularly in lung cancer.
Targeted Therapies:
Small molecule inhibitors (SMIs) targeting VEGFR, BRAF, or EGFR can also enhance T-cell infiltration and function.
Other Potential Agents:
Vitamin D, antidepressants (SSRIs), bisphosphonates, and TGF-inhibitors.
Cancer Biology & Medicine
+6
Potential Advantages
Improved Efficacy:
Combining these agents with ICIs like nivolumab or pembrolizumab can reduce tumor growth more effectively than either agent alone.
Reduced Side Effects:
Some repurposed drugs can decrease immune-related adverse events.
Lower Costs:
Repurposed drugs are generally affordable and already approved for safety.
Cancer Biology & Medicine
+4
3
